
Luminex Corporation – NASDAQ:LMNX
Luminex stock price today
Luminex stock price yearly change
Luminex key metrics
Market Cap | N/A |
Enterprise value | 1.68B |
P/E | 71.93 |
EV/Sales | 3.84 |
EV/EBITDA | 29.89 |
Price/Sales | 3.87 |
Price/Book | 3.47 |
PEG ratio | 0.15 |
EPS | 0.52 |
Revenue | 437.66M |
EBITDA | 56.36M |
Income | 23.59M |
Revenue Q/Q | 22.40% |
Revenue Y/Y | 27.72% |
Profit margin | 5.39% |
Oper. margin | 12.4% |
Gross margin | 60.31% |
EBIT margin | 12.4% |
EBITDA margin | 12.88% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLuminex stock price history
Luminex stock forecast
Luminex financial statements
Jun 2020 | 109.51M | 12.51M | 11.42% |
---|---|---|---|
Sep 2020 | 106.06M | 1.76M | 1.67% |
Dec 2020 | 111.39M | 239K | 0.21% |
Mar 2021 | 110.68M | 9.08M | 8.21% |
2020-11-05 | 0.2 | 0.04 |
---|---|---|
2021-02-08 | 0.13 | 0.01 |
Payout ratio | 0% |
---|
2016 | |
---|---|
2017 | 0.93% |
2018 | 1.04% |
2019 | 1.19% |
2020 | 1.56% |
Jun 2020 | 784177000 | 279.91M | 35.7% |
---|---|---|---|
Sep 2020 | 810945000 | 294.84M | 36.36% |
Dec 2020 | 770118000 | 307.75M | 39.96% |
Mar 2021 | 819031000 | 330.98M | 40.41% |
Jun 2020 | 31.27M | -4.17M | 221.56M |
---|---|---|---|
Sep 2020 | 14.94M | -3.51M | 5.75M |
Dec 2020 | 10.92M | -6.29M | -3.12M |
Mar 2021 | -21.56M | -13.44M | -3.28M |
Luminex alternative data
Aug 2023 | 1,325 |
---|---|
Sep 2023 | 1,325 |
Oct 2023 | 1,325 |
Nov 2023 | 1,325 |
Dec 2023 | 1,325 |
Jan 2024 | 1,325 |
Feb 2024 | 1,325 |
Mar 2024 | 1,325 |
Apr 2024 | 1,325 |
May 2024 | 1,325 |
Jun 2024 | 1,325 |
Jul 2024 | 1,325 |
Luminex other data
Period | Buy | Sel |
---|---|---|
Apr 2020 | 0 | 250000 |
May 2020 | 0 | 95998 |
Jun 2020 | 0 | 200000 |
Jul 2020 | 0 | 313366 |
Aug 2020 | 0 | 360813 |
Nov 2020 | 4487 | 0 |
Feb 2021 | 0 | 121507 |
Mar 2021 | 0 | 5325 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | CURRIE HARRISS T officer: SVP, Finance & CFO | Stock Option (Right To Buy) | 5,325 | $18.26 | $97,235 | ||
Sale | CURRIE HARRISS T officer: SVP, Finance & CFO | Common Stock | 5,325 | $18.26 | $97,235 | ||
Option | CURRIE HARRISS T officer: SVP, Finance & CFO | Common Stock | 5,325 | $18.26 | $97,235 | ||
Option | BENNETT TODD C. officer: SVP, Global Sales & Cu.. | Common Stock | 121,507 | $19.34 | $2,349,945 | ||
Option | BENNETT TODD C. officer: SVP, Global Sales & Cu.. | Stock Option (Right To Buy) | 62,944 | $20.1 | $1,264,860 | ||
Sale | BENNETT TODD C. officer: SVP, Global Sales & Cu.. | Common Stock | 121,507 | $33.81 | $4,108,152 | ||
Purchase | ECK STEPHEN L. director | Common Stock | 4,487 | $22.4 | $100,513 | ||
Sale | FAIRCHILD NANCY officer: SVP, Human Resources | Common Stock | 24,283 | $40.16 | $975,205 | ||
Option | SHAMIR NACHUM director, officer: President & .. | Stock Option (Right To Buy) | 8,559 | $40.16 | $343,729 | ||
Sale | SHAMIR NACHUM director, officer: President & .. | Common Stock | 8,559 | $40.16 | $343,729 |
Patent |
---|
Application Filling date: 25 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 31 Mar 2022 Issue date: 11 Aug 2022 |
Grant Utility: Cleavable hairpin primers Filling date: 8 May 2020 Issue date: 28 Jun 2022 |
Grant Filling date: 21 Nov 2019 Issue date: 28 Jun 2022 |
Grant Design: Sample processing instrument Filling date: 22 Feb 2021 Issue date: 7 Jun 2022 |
Application Filling date: 31 Jan 2022 Issue date: 19 May 2022 |
Grant Filling date: 23 Jan 2020 Issue date: 3 May 2022 |
Grant Filling date: 28 Feb 2020 Issue date: 1 Mar 2022 |
Application Filling date: 7 Jul 2021 Issue date: 13 Jan 2022 |
Application Filling date: 18 Jun 2021 Issue date: 7 Oct 2021 |
Quarter | Transcript |
---|---|
Q4 2020 8 Feb 2021 | Q4 2020 Earnings Call Transcript |
Q2 2020 5 Aug 2020 | Q2 2020 Earnings Call Transcript |
Q1 2020 5 May 2020 | Q1 2020 Earnings Call Transcript |
Q4 2019 11 Feb 2020 | Q4 2019 Earnings Call Transcript |
-
What's the price of Luminex stock today?
One share of Luminex stock can currently be purchased for approximately $36.99.
-
When is Luminex's next earnings date?
Unfortunately, Luminex's (LMNX) next earnings date is currently unknown.
-
Does Luminex pay dividends?
No, Luminex does not pay dividends.
-
What is Luminex's stock symbol?
Luminex Corporation is traded on the NASDAQ under the ticker symbol "LMNX".
-
What is Luminex's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Luminex?
Shares of Luminex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Luminex have?
As Jul 2024, Luminex employs 1,325 workers.
-
When Luminex went public?
Luminex Corporation is publicly traded company for more then 25 years since IPO on 30 Mar 2000.
-
What is Luminex's official website?
The official website for Luminex is luminexcorp.com.
-
Where are Luminex's headquarters?
Luminex is headquartered at 12212 Technology Blvd, 512-219-8020, Austin, TEXAS.
-
How can i contact Luminex?
Luminex's mailing address is 12212 Technology Blvd, 512-219-8020, Austin, TEXAS and company can be reached via phone at +1 512 249 4741.
Luminex company profile:

Luminex Corporation
luminexcorp.comNASDAQ
1,325
Medical - Instruments & Supplies
Healthcare
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Austin, TEXAS 78727
CIK: 0001033905
ISIN: US55027E1029
CUSIP: 55027E102